Recent Finacing
Recent Raise
Arrevus develops therapeutics for orphan diseases, advancing ARV-1801 (sodium fusidate)—an antibacterial, anti-inflammatory, mucolytic agent acquired from Melinta—into Phase 3 for cystic fibrosis pulmonary exacerbations.
Focus Areas
Recent Investors
Funding round
Investor
See the team members at Arrevus.
